Immunology & Autoimmune
Part of Biotech - Drug Development
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 JNJ | Johnson & Johnson | $0.5t | $228.05 | +0.6% | 3.0M |
 ABBV | ABBVIE INC. | $349.7b | $208.34 | -1.0% | 2.0M |
 AMGN | Amgen Inc | $183.1b | $323.88 | -0.7% | 802.1K |
 BMY | Bristol-Myers Squibb Co. | $119.0b | $57.59 | +1.0% | 6.3M |
 REGN | Regeneron Pharmaceuticals Inc | $76.7b | $631.01 | -9.6% | 2.2M |
 ROIV | Roivant Sciences Ltd. Common Shares | $19.9b | $28.52 | -2.6% | 2.0M |
 APGE | Apogee Therapeutics, Inc. Common Stock | $7.6b | $80.01 | -1.4% | 319.2K |
 IBRX | ImmunityBio, Inc. Common Stock | $7.2b | $7.97 | +0.1% | 7.8M |
 PTGX | Protagonist Therapeutics, Inc | $6.5b | $101.63 | -0.5% | 184.6K |
 SYRE | Spyre Therapeutics, Inc. Common Stock | $5.9b | $70.48 | -5.9% | 451.1K |
 TGTX | TG Therapeutics, Inc. | $5.5b | $39.58 | +0.2% | 710.2K |
 IMVT | Immunovant, Inc. Common Stock | $5.5b | $26.49 | -3.6% | 498.9K |
 APLS | Apellis Pharmaceuticals, Inc. Common Stock | $5.2b | $41.04 | +0.0% | 68.6M |
 DNTH | Dianthus Therapeutics, Inc. Common Stock | $4.6b | $82.21 | -4.6% | 319.6K |
 ORKA | Oruka Therapeutics, Inc. Common Stock | $3.7b | $59.16 | -4.5% | 1.0M |
 RCUS | Arcus Biosciences, Inc. | $3.1b | $23.77 | -0.0% | 625.0K |
 ALMS | Alumis Inc. Common Stock | $3.1b | $20.98 | -8.3% | 667.0K |
 ARQT | Arcutis Biotherapeutics, Inc. Common Stock | $2.9b | $20.10 | -5.7% | 710.4K |
 NKTR | Nektar Therapeutics | $2.8b | $67.20 | -4.8% | 654.5K |
 VERA | Vera Therapeutics, Inc. Class A Common Stock | $2.7b | $34.03 | -8.8% | 668.2K |
 CLDX | Celldex Therapeutics, Inc | $2.6b | $29.79 | -5.0% | 401.8K |
 ADMA | ADMA Biologics, Inc. | $2.5b | $8.34 | +0.8% | 1.4M |
 AUPH | Aurinia Pharmaceuticals Inc | $2.1b | $15.57 | +1.9% | 598.5K |
 ANAB | AnaptysBio, Inc. Common Stock | $1.9b | $59.37 | -6.0% | 268.5K |
 BHVN | Biohaven Ltd. | $1.4b | $8.56 | -2.3% | 985.3K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.3b | $11.94 | -3.0% | 1.7M |
 JBIO | Jade Biosciences, Inc. Common Stock | $1.3b | $21.98 | -5.9% | 224.5K |
 DBVT | DBV Technologies S.A. | $1.2b | $18.91 | -3.8% | 96.1K |
 MLTX | MoonLake Immunotherapeutics Class A Ordinary Shares | $1.2b | $16.48 | -6.1% | 509.3K |
 ZBIO | Zenas BioPharma, Inc. Common Stock | $1.1b | $16.86 | -8.1% | 413.3K |
 SEPN | Septerna, Inc. Common Stock | $1.1b | $26.39 | -2.1% | 172.5K |
 ANNX | Annexon, Inc. Common Stock | $1.0b | $5.01 | -3.8% | 1.7M |
 EVMN | Evommune, Inc. | $0.9b | $21.98 | -4.1% | 264.6K |
 XNCR | Xencor, Inc. | $0.9b | $11.14 | -0.7% | 431.0K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $0.8b | $15.26 | -3.0% | 1.4M |
 ACRS | Aclaris Therapeutics, Inc. | $0.6b | $4.29 | -5.0% | 658.2K |
 STTK | Shattuck Labs, Inc. Common Stock | $0.6b | $5.92 | -5.4% | 398.2K |
 RIGL | Rigel Pharmaceuticals Inc. (New) | $0.6b | $28.63 | -1.3% | 243.4K |
 KYTX | Kyverna Therapeutics, Inc. Common Stock | $0.5b | $8.65 | -8.8% | 957.8K |
 UPB | Upstream Bio, Inc. Common Stock | $0.5b | $8.17 | -10.1% | 215.9K |
 FBRX | Forte Biosciences, Inc. Common Stock | $0.5b | $21.00 | -9.1% | 129.4K |
 ZURA | Zura Bio Limited Class A Ordinary Shares | $0.5b | $4.24 | -10.2% | 243.1K |
 IMMX | Immix Biopharma, Inc. Common Stock | $455.9m | $9.26 | -6.8% | 311.5K |
 CLYM | Climb Bio, Inc. Common Stock | $442.3m | $9.85 | -8.8% | 385.4K |
 ENTA | Enanta Pharmaceuticals, Inc | $397.9m | $13.45 | +0.3% | 131.5K |
 IPSC | Century Therapeutics, Inc. Common Stock | $396.8m | $2.27 | -3.2% | 878.5K |
 PALI | Palisade Bio, Inc. Common Stock | $326.9m | $1.83 | +0.3% | 1.7M |
 CABA | Cabaletta Bio, Inc. Common Stock | $318.4m | $3.23 | -2.6% | 1.4M |
 AVTX | Avalo Therapeutics, Inc. Common Stock | $293.1m | $15.95 | -10.1% | 1.1M |
 SABS | SAB Biotherapeutics, Inc. Common Stock | $248.1m | $3.50 | -5.5% | 464.9K |